Repackaging Compounder


In a recently posted USFDA warning letter, a compounder repackaging Avastin for ophthalmic use was doing so in a clean room with a wall mounted air conditioning unit and no adequate system for cleaning and disinfecting the room or equipment to produce aseptic conditions.  Additionally, the gowns worn by production personnel were not sterile.